Solara Active Pharma Sciences Ltd
NSE:SOLARA

Watchlist Manager
Solara Active Pharma Sciences Ltd Logo
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Watchlist
Price: 824.85 INR 0.28% Market Closed
Market Cap: 39.6B INR
Have any thoughts about
Solara Active Pharma Sciences Ltd?
Write Note

Solara Active Pharma Sciences Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Solara Active Pharma Sciences Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Current Portion of Long-Term Debt
â‚ą7.4B
CAGR 3-Years
8%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Current Portion of Long-Term Debt
â‚ą14B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Current Portion of Long-Term Debt
â‚ą2.4B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Current Portion of Long-Term Debt
â‚ą22B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Current Portion of Long-Term Debt
â‚ą16.5B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Current Portion of Long-Term Debt
â‚ą231.2m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Solara Active Pharma Sciences Ltd
Glance View

Market Cap
39.6B INR
Industry
Pharmaceuticals

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.

SOLARA Intrinsic Value
539.22 INR
Overvaluation 35%
Intrinsic Value
Price

See Also

What is Solara Active Pharma Sciences Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
7.4B INR

Based on the financial report for Sep 30, 2024, Solara Active Pharma Sciences Ltd's Current Portion of Long-Term Debt amounts to 7.4B INR.

What is Solara Active Pharma Sciences Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
44%

Over the last year, the Current Portion of Long-Term Debt growth was -6%. The average annual Current Portion of Long-Term Debt growth rates for Solara Active Pharma Sciences Ltd have been 8% over the past three years , 44% over the past five years .

Back to Top